E 4177

Subscribe to Selected New Research on E 4177

8 relevant articles (3 outcomes, 1 trials/studies) found for this Bio-Agent

Description: a non-peptide angiotensin II-receptor antagonist; structure given in first source

Also Known As:

(1,1'-Biphenyl)-2-carboxylic acid, 4'-((2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridin-3-yl)methyl)-; 3-((2'-carboxybiphenyl-4-yl)methyl)-2-cyclopropyl-7-methyl-3H-imidazo(4,5-b)pyridine; E-4177; E4177

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Related Diseases

1.	Necrosis 08/01/1999 - "Similarly, degeneration and necrosis of glomeruli were also markedly improved by cilazapril and E-4177 (P<0.01)" 08/01/1999 - "Degeneration and necrosis of tubules were significantly improved by cilazapril and E-4177 treatment (P<0.01)" 08/01/1999 - "Moreover, cilazapril, E-4177, and hydralazine significantly decreased the thickening and necrosis of blood vessels compared with vehicle" Get all the results and reference details, order at left...
2.	Hypertrophy 11/01/1997 - "Glomerulosclerosis and glomerular hypertrophy in OLETF rats were improved by cilazapril and E4177 to a comparable extent" Get all the results and reference details, order at left...
3.	Hypertension (High Blood Pressure) 07/01/1993 - "These data indicate that E4177 is a potent AT1 Ang II-receptor antagonist that may be clinically useful for the treatment of cardiovascular diseases such as hypertension." Get all the results and reference details, order at left...
4.	Cardiovascular Diseases (Cardiovascular Disease) 07/01/1993 - "These data indicate that E4177 is a potent AT1 Ang II-receptor antagonist that may be clinically useful for the treatment of cardiovascular diseases such as hypertension." Get all the results and reference details, order at left...
5.	Myocardial Infarction 03/01/1996 - "The objective of the present study was to evaluate the hemodynamic, biochemical, and morphological responses to Ang II receptor blockade with E-4177, 3-[(2'-carboxybiphenyl-4-yl) methyl]-2-cyclopropyl-7-methyl 3H-imidazol[4,5-b] pyridine, in rats with a healing myocardial infarction that had been induced by the surgical occlusion of the left main coronary artery" Get all the results and reference details, order at left...
12 Diseases and 8 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Cilazapril
2.	benzocycloheptapyridine
3.	Angiotensin Receptors (Angiotensin II Receptor)
4.	Phentolamine (Z-Max)
5.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
6.	Insulin (Novolin)
7.	Hydralazine (Apresoline)
8.	Glucose (Dextrose)
9.	Epinephrine (Adrenaline)
10.	Enalapril
11 Drugs and Important Bio-Agents and 6 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>